These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 35371064)

  • 1. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
    Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():845969. PubMed ID: 35371064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
    Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
    Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.
    Mooij P; García-Arriaza J; Pérez P; Lázaro-Frías A; Verstrepen BE; Böszörményi KP; Mortier D; Fagrouch Z; Kiemenyi-Kayere G; Niphuis H; Acar RF; Meijer L; Stammes MA; Kondova I; Verschoor EJ; GeurtsvanKessel CH; de Bruin E; Sikkema RS; Luczkowiak J; Delgado R; Montenegro D; Puentes E; Rodríguez E; Bogers WMJM; Koopman G; Esteban M
    Front Immunol; 2022; 13():845887. PubMed ID: 35371043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; López-Bravo M; Zamora C; Sin L; Álvarez E; Sorzano CÓS; Sánchez-Cordón PJ; Casasnovas JM; Astorgano D; García-Arriaza J; Anthiya S; Borrajo ML; Lou G; Cuesta B; Franceschini L; Gelpí JL; Thielemans K; Sisteré-Oró M; Meyerhans A; García F; Esteban I; López-Bigas N; Plana M; Alonso MJ; Esteban M; Gómez CE
    Emerg Microbes Infect; 2024 Dec; 13(1):2387906. PubMed ID: 39087555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
    García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Gómez-Carballa A; Albericio G; Montoto-Louzao J; Pérez P; Astorgano D; Rivero-Calle I; Martinón-Torres F; Esteban M; Salas A; García-Arriaza J
    Antiviral Res; 2023 Dec; 220():105760. PubMed ID: 37992765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
    Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
    Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
    Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE
    Front Immunol; 2023; 14():1160065. PubMed ID: 37404819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
    Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
    Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
    Meyer Zu Natrup C; Tscherne A; Dahlke C; Ciurkiewicz M; Shin DL; Fathi A; Rohde C; Kalodimou G; Halwe S; Limpinsel L; Schwarz JH; Klug M; Esen M; Schneiderhan-Marra N; Dulovic A; Kupke A; Brosinski K; Clever S; Schünemann LM; Beythien G; Armando F; Mayer L; Weskamm ML; Jany S; Freudenstein A; Tuchel T; Baumgärtner W; Kremsner P; Fendel R; Addo MM; Becker S; Sutter G; Volz A
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36301637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
    Meseda CA; Stauft CB; Selvaraj P; Lien CZ; Pedro C; Nuñez IA; Woerner AM; Wang TT; Weir JP
    NPJ Vaccines; 2021 Dec; 6(1):145. PubMed ID: 34862398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.